Shire PLC (LON:SHP) Director Mark Clayton Jarvis sold 365,000 shares of Shire stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of GBX 0.06 ($0.00), for a total value of £219 ($302.57).
Shares of Shire PLC (SHP) opened at GBX 3,205.50 ($44.29) on Friday. The company has a market capitalization of $29,140.00 and a PE ratio of 2,210.69. Shire PLC has a 12 month low of GBX 2,940.50 ($40.63) and a 12 month high of GBX 5,021 ($69.37).
The company also recently announced a dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Thursday, March 8th will be paid a GBX 21.46 ($0.30) dividend. The ex-dividend date is Thursday, March 8th. This is an increase from Shire’s previous dividend of $3.85. This represents a dividend yield of 0.67%.
Several research firms have recently weighed in on SHP. Societe Generale reissued a “buy” rating and issued a GBX 7,500 ($103.62) price objective on shares of Shire in a research report on Wednesday. Liberum Capital reissued a “hold” rating and issued a GBX 4,000 ($55.26) price objective on shares of Shire in a research report on Wednesday, March 7th. Credit Suisse Group reissued an “outperform” rating and issued a GBX 4,000 ($55.26) price objective on shares of Shire in a research report on Monday, March 5th. Shore Capital reissued a “buy” rating on shares of Shire in a research report on Friday, February 23rd. Finally, Berenberg Bank lowered their price objective on Shire from GBX 6,000 ($82.90) to GBX 4,500 ($62.17) and set a “buy” rating for the company in a research report on Friday, February 23rd. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of GBX 4,955.88 ($68.47).
TRADEMARK VIOLATION WARNING: “Shire PLC (SHP) Director Sells £219 in Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/18/shire-plc-shp-director-sells-219-in-stock.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.